Trial · NCT05323656
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Percentage Change in Tumour Size | Setanaxib 1600 mg and Pembrolizumab 200 mg | -7.88 | Standard Error 9.323 | Percentage change from baseline | |
| Best Percentage Change in Tumour Size | Placebo and Pembrolizumab 200 mg | -12.93 | Standard Error 8.977 | Percentage change from baseline | |
| Progression Free Survival (PFS) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 151 | 80% Confidence Interval 125 to 229 | days | |
| Progression Free Survival (PFS) | Placebo and Pembrolizumab 200 mg | 87 | 80% Confidence Interval 65 to 117 | days | |
| Change From Baseline in Cancer-associated Fibroblasts (CAFs) Level in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Baseline | 58.13 | Standard Deviation 37.006 | % positivity of tumour stromal component |
| Change From Baseline in Cancer-associated Fibroblasts (CAFs) Level in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Baseline | 52.00 | Standard Deviation 23.357 | % positivity of tumour stromal component |
| Change From Baseline in Cancer-associated Fibroblasts (CAFs) Level in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 50.50 | Standard Deviation 31.023 | % positivity of tumour stromal component |
| Change From Baseline in Cancer-associated Fibroblasts (CAFs) Level in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Week 9 | 36.50 | Standard Deviation 30.373 | % positivity of tumour stromal component |
| Change From Baseline in the Number of Cluster of Differentiation 8 (CD8+) Tumour Infiltrating Lymphocytes (TILs) in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Baseline | 18.13 | Standard Deviation 8.901 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Cluster of Differentiation 8 (CD8+) Tumour Infiltrating Lymphocytes (TILs) in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Baseline | 21.34 | Standard Deviation 19.789 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Cluster of Differentiation 8 (CD8+) Tumour Infiltrating Lymphocytes (TILs) in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 41.14 | Standard Deviation 34.535 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Cluster of Differentiation 8 (CD8+) Tumour Infiltrating Lymphocytes (TILs) in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Week 9 | 38.30 | Standard Deviation 26.553 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Regulatory T-cells in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Baseline | 9.75 | Standard Deviation 9.955 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Regulatory T-cells in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Baseline | 24.36 | Standard Deviation 27.104 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Regulatory T-cells in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 21.14 | Standard Deviation 22.879 | cells/High Power Field (HPF) |
| Change From Baseline in the Number of Regulatory T-cells in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Week 9 | 30.16 | Standard Deviation 38.866 | cells/High Power Field (HPF) |
| Overall Response Rate (ORR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Complete Response | 1 | Participants | |
| Overall Response Rate (ORR) | Placebo and Pembrolizumab 200 mg | Complete Response | 0 | Participants | |
| Overall Response Rate (ORR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Partial Response | 8 | Participants | |
| Overall Response Rate (ORR) | Placebo and Pembrolizumab 200 mg | Partial Response | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/results